Heidi Ko/LinkedIn
Dec 18, 2024, 06:55
Heidi Ko: Honored to present on patient awareness of HER2-low breast cancer at SABCS24
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared a post on LinkedIn:
“I’m so honored to present this study on patient awareness of HER2-low breast cancer, led by amazing Rebecca Previs, Labcorp and Outcomes4Me SABCS24.
We deployed a six-month patient-centric educational campaign around HER2 testing and HER2-low mBC.
A pre-campaign survey showed
- 41.9% of patients with a known HER2 status were not at all aware or not very aware of the HER2-low classification.
- 51% with HER2-negative on recent testing did not recall their oncologist discussing HER2-low as a possibility
Patient awareness gaps exist around relevant biomarker testing.
After engaging with the campaign, 60.9% with unknown HER2 status felt very or somewhat likely to talk to their oncologist about testing for HER2-low.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 18, 2024, 06:52
Dec 18, 2024, 06:40
Dec 18, 2024, 05:00
Dec 18, 2024, 03:36
Dec 18, 2024, 02:49
Dec 17, 2024, 23:36